Approval · Notice of Compliance 31159 · 2023
VFEND: Notice of Compliance 31159
Issued July 6, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31159
- Date
- July 6, 2023
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph (PM) with a risk of skin toxicity with concomitant administration of methotrexate.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VFEND | Not yet assigned | — |
Medicinal ingredients
- VORICONAZOLE 50 MG per TAB
- VORICONAZOLE 200 MG per TAB
- VORICONAZOLE 200 MG per VIAL
- VORICONAZOLE 200 MG per 5ML